中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

26 records (took 0.019 seconds)

    Use of alicyclic diamines as immunomodulators
    14.
    发明授权
    Use of alicyclic diamines as immunomodulators 失效
    使用脂环族二胺作为免疫调节剂

    公开(公告)号：US06228890B1

    公开(公告)日：2001-05-08

    申请号：US09011145

    申请日：1998-06-03

    Applicant: Jean-Claude Maziere ,  Amar Achour ,  Jean-Charles Landureau ,  Daniel Zagury

    Inventor： Jean-Claude Maziere ,  Amar Achour ,  Jean-Charles Landureau ,  Daniel Zagury

    IPC: A61K3113

    CPC classification number: A61K31/137 ,  A61K31/13 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/423

    Abstract: The invention discloses the use of a compound of general structural formula (I) R-NH-K-Q-K-NH-R, wherein Q is a divalent radical of formulae (II) to (V), K is a methylene group, or, when Q is a group of formula (II), K is a binding valency. R is a radical selected from the group comprising benzyl, benzyl substituted with halogen or trihalomethyl groups, substituted trihalomethyl benzyl, indanyl, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, cycloalkenylalkyl, bicycloalkyl, bicycloalkenylalkyl, bicycloalkylalkyl; and the organic or mineral acid addition salts thereof. The preparation of a medicament for correcting the expression of cytokine genes and/or a receptor thereof for treating a dysfunction related to an exogenous or endogenous disease state is also described.

    Abstract translation: 本发明公开了通式（I）R-NH-KQK-NH-R化合物的用途，其中Q为式（II）至（V）的二价基团，K为亚甲基，或 Q是式（II）的基团，K是结合价。 R是选自苄基，被卤素或三卤甲基取代的苄基，取代的三卤甲基苄基，茚满基，烷基，环烷基，环烷基烷基，烯基，环烯基烷基，双环烷基，双环烯基烷基，双环烷基烷基; 及其有机或无机酸加成盐。 还描述了用于校正细胞因子基因和/或其受体的表达以治疗与外源性或内源性疾病状态相关的功能障碍的药物的制备。

    Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them
    15.
    发明授权
    Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them 有权
    衍生自逆转录病毒调节蛋白抗体制备方法的非毒性免疫原和包含它们的药物组合物

    公开(公告)号：US06200575B1

    公开(公告)日：2001-03-13

    申请号：US09570915

    申请日：2000-05-15

    Applicant: Jean-François Zagury ,  Bernard Bizzini ,  Daniel Zagury

    Inventor： Jean-François Zagury ,  Bernard Bizzini ,  Daniel Zagury

    IPC: A61K3921

    CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  C07K16/1072 ,  C12N2740/16322 ,  Y10S530/826

    Abstract: A non-toxic immunogenic compound, which may be administered to humans, is derived from an HIV-1, HIV-2, HTLV-1 or HTLV-2 viral regulatory protein by chemical processing using a coupling agent such as an aldehyde, or from a carrier protein activated by pre-processing using an aldehyde. This compound is capable of being recognized by antibodies to the viral regulatory protein and retains sufficient immunogenic properties to produce antibodies that neutralize or block the native protein, while losing at least 50% of the toxic biological properties of the native protein.

    Abstract translation: 可以向人施用的无毒免疫原性化合物通过使用偶联剂如醛或通过化学处理从HIV-1，HIV-2，HTLV-1或HTLV-2病毒调节蛋白衍生自 通过使用醛进行预处理而活化的载体蛋白。 该化合物能够被病毒调节蛋白的抗体识别并保留足够的免疫原性，以产生中和或阻断天然蛋白质的抗体，同时损失天然蛋白质的毒性生物学性质的至少50％。

    Chemically modified cytokines
    16.
    发明授权
    Chemically modified cytokines 有权
    化学修饰的细胞因子

    公开(公告)号：US07208148B2

    公开(公告)日：2007-04-24

    申请号：US11084175

    申请日：2005-03-21

    Applicant: Daniel Zagury ,  Jean-François Zagury

    Inventor： Daniel Zagury ,  Jean-François Zagury

    IPC: A61K38/19 ,  A61K38/20 ,  A61K38/21

    CPC classification number: C07K14/5412 ,  A61K38/00 ,  A61K39/00 ,  A61K47/646 ,  C07K14/525 ,  C07K14/5406 ,  C07K14/5428 ,  C07K14/5437 ,  C07K14/545 ,  C07K14/57

    Abstract: The invention concerns a derivative of viral regulatory protein or a fragment of viral regulatory protein or of the alpha interferon or a fragment of alpha interferon, which is carboxymethylated, a method for preparing, use of the resulting product in a method of treatment for the human or animal body, a pharmaceutical composition and a vaccine containing as active principle, at least one of the carboxymethylated proteins or fragments.

    Abstract translation: 本发明涉及病毒调节蛋白的衍生物或病毒调节蛋白的片段或α干扰素的片段或α-干扰素的片段，其是羧甲基化的，在所述人的治疗方法中制备，使用所得产物的方法 或动物体，药物组合物和含有作为活性成分的至少一种羧甲基化蛋白质或片段的疫苗。

    Method for determining prognosis of HIV infected individuals
    17.
    发明授权
    Method for determining prognosis of HIV infected individuals 失效
    确定艾滋病毒感染者预后的方法

    公开(公告)号：US07067246B1

    公开(公告)日：2006-06-27

    申请号：US09763369

    申请日：1999-08-20

    Applicant: Daniel Zagury ,  Jean-Francois Zagury

    Inventor： Daniel Zagury ,  Jean-Francois Zagury

    IPC: C12Q1/70

    CPC classification number: G01N33/56988 ,  G01N2333/163

    Abstract: The serum levels of anti-tat antibodies, tat protein, and p24 protein are predictive of disease progression in HIV infected individuals and serve as prognostic markers. The present invention relates to a method for determining the prognosis of an HIV infected individual by measuring serum levels of one or more of these prognostic markers. In addition, a method for monitoring whether an HIV infected individual is in need of immunization with a tat vaccine and a method for monitoring the efficacy of immunization with a tat vaccine are also disclosed.

    Abstract translation: 抗tat抗体，tat蛋白和p24蛋白的血清水平预测HIV感染个体的疾病进展，并且作为预后标志物。 本发明涉及通过测量这些预后标志物中的一种或多种的血清水平来确定HIV感染个体的预后的方法。 此外，还公开了一种用于监测HIV感染个体是否需要用tat疫苗进行免疫的方法以及用tat监测免疫接种效力的方法。

    Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory IgA's
    18.
    发明授权
    Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory IgA's 有权
    使用灭活的免疫抑制或血管生成免疫原性蛋白来产生分泌型IgA

    公开(公告)号：US07015016B2

    公开(公告)日：2006-03-21

    申请号：US10168115

    申请日：2000-12-14

    Applicant: Daniel Zagury

    Inventor： Daniel Zagury

    IPC: C12P21/06

    CPC classification number: C07K16/18 ,  A61K9/0043 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/541 ,  A61K2039/542 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55544 ,  A61K2039/55566 ,  A61K2039/585 ,  C07K16/1036 ,  C07K16/1063 ,  C12N2740/16034 ,  C12N2740/16134 ,  C12N2740/16334

    Abstract: The invention concerns the use of a protein derived from cancel cells, cells infected by a virus or immune cells or an inactive fragment of said protein, said protein being initially an immunosuppressive and/or an angiogenic protein with local activity whereof said properties have been inactivated by at least 70% by a physical and/or chemical treatment, such as formolisation, carboxamidation, carboxymethylation, maleimidation or oxidation by oxygen bubbling, by genetic recombination or by adjuvant conditioning, said treatment preserving its property of being identified by antibodies directed against said protein, and preserving sufficient immunogenic properties for generating antibodies neutralizing or blocking said native protein, or the use of a DNA molecule corresponding to said protein inactivated by mutation or to said inactive fragment, for obtaining a medicine designed to provide a patient with mucosal immunity based on secretion of IgA secretory antibodies, pharmaceutical compositions for the mucous membranes and IgA antibodies.

    Abstract translation: 本发明涉及来自消除细胞的蛋白质，由病毒或免疫细胞感染的细胞或所述蛋白质的无活性片段的用途，所述蛋白质最初是免疫抑制剂和/或具有局部活性的血管生成蛋白质，其中所述性质已被灭活 通过物理和/或化学处理如至少70％，通过基本重组或通过辅助调理来形成，例如甲酰化，羧甲酰化，羧甲基化，马来酰亚胺化或氧化，所述处理保持其被针对所述 蛋白质，并且保留足够的免疫原性，产生中和或阻断所述天然蛋白质的抗体，或使用对应于通过突变而灭活的所述蛋白质的DNA分子或所述非活性片段获得旨在为患者提供基于粘膜免疫的药物 对IgA分泌抗体的分泌，药物组合物 粘膜和IgA抗体的情况。

Patent Agency Ranking